Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

NCT03181308 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Carotuximab (TRC105)
DRUG: OPDIVO

Sponsor

Tracon Pharmaceuticals Inc.